BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25688965)

  • 1. Utilisation of co-testing 
(human papillomavirus DNA testing and cervical cytology) after treatment of CIN: - a survey of GPs' awareness and knowledge.
    Munro A; Codde J; Semmens J; Leung Y; Spilsbury K; Williams V; Steel N; Cohen P; Pavicic H; Westoby V; O'Leary P
    Aust Fam Physician; 2015; 44(1-2):64-8. PubMed ID: 25688965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
    Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
    J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can the careHPV test performed in mobile units replace cytology for screening in rural and remote areas?
    Lorenzi AT; Fregnani JH; Possati-Resende JC; Antoniazzi M; Scapulatempo-Neto C; Syrjänen S; Villa LL; Longatto-Filho A
    Cancer Cytopathol; 2016 Aug; 124(8):581-8. PubMed ID: 27070446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rescreening of high-risk HPV positive Papanicolaou tests initially screened as negative is a low yield procedure in the era of HPV genotyping.
    Narkcham S; Mody DR; Jones A; Thrall MJ
    J Am Soc Cytopathol; 2021; 10(6):558-564. PubMed ID: 34103275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
    Ge Y; Christensen P; Luna E; Armylagos D; Schwartz MR; Mody DR
    Cancer Cytopathol; 2017 Aug; 125(8):652-657. PubMed ID: 28574670
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of HPV DNA Testing in Follow-up after Loop Electrosurgical Excision Procedures in Northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Kietpeerakool C; Tantipalakorn C; Suprasert P; Siriaunkgul S
    Asian Pac J Cancer Prev; 2015; 16(14):6093-7. PubMed ID: 26320501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-grade squamous intraepithelial lesion, cannot rule out high-grade lesion: Diagnosis, histological outcomes and human papillomavirus results.
    Segura SE; Ramos-Rivera G; Hakima L; Suhrland M; Khader S
    Cytopathology; 2019 Jan; 30(1):99-104. PubMed ID: 30187975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of human papillomavirus genotypes and precancerous cervical lesions in a screening population in the Republic of Korea, 2014-2016.
    Ouh YT; Min KJ; Cho HW; Ki M; Oh JK; Shin SY; Hong JH; Lee JK
    J Gynecol Oncol; 2018 Jan; 29(1):e14. PubMed ID: 29185272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of cervical high-grade squamous intraepithelial lesions and squamous cell carcinoma in women with high-risk human papillomavirus and normal cervical cytology: A retrospective analysis of 1858 cases stratified by age and human papillomavirus genotype.
    Gu L; Hong Z; Gao H; Qiu L; Di W
    Cytopathology; 2019 Jul; 30(4):419-425. PubMed ID: 31069857
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
    Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
    Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Performance of HPV DNA testing with hybrid capture 2 in triaging women with minor cervical cytologic abnormalities (ASC-US/LSIL) in Northern Thailand.
    Khunamornpong S; Settakorn J; Sukpan K; Srisomboon J; Suprasert P; Siriaunkgul S
    Asian Pac J Cancer Prev; 2014; 15(24):10961-6. PubMed ID: 25605209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the diagnostic value of cervical cytology and HPV HR DNA testing for the diagnosis of low-grade and high-grade squamous intraepithelial lesions across different age groups.
    Paluszkiewicz A; Pruski D; Iwaniec K; Kędzia W
    Ginekol Pol; 2017; 88(3):141-146. PubMed ID: 28397203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are vaginal swabs comparable to cervical smears for human papillomavirus DNA testing?
    Coorevits L; Traen A; Bingé L; Van Dorpe J; Praet M; Boelens J; Padalko E
    J Gynecol Oncol; 2018 Jan; 29(1):e8. PubMed ID: 29185266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
    Zhang H; Varma KR; Han M; Matsko J; Zhao C
    Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of human papillomavirus types in ThinPrep Papanicolaou tests classified according to the Bethesda 2001 terminology and correlations with patient age and biopsy outcomes.
    Evans MF; Adamson CS; Papillo JL; St John TL; Leiman G; Cooper K
    Cancer; 2006 Mar; 106(5):1054-64. PubMed ID: 16421920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical value of p16
    Song FB; Du H; Xiao AM; Wang C; Huang X; Yan PS; Liu ZH; Qu XF; Belinson JEROMEL; Wu RF
    Zhonghua Fu Chan Ke Za Zhi; 2020 Nov; 55(11):784-790. PubMed ID: 33228350
    [No Abstract]   [Full Text] [Related]  

  • 18. Screening for persistent high-risk HPV infections may be a valuable screening method for young women; A retrospective cohort study.
    Ebisch RMF; Ketelaars PJW; van der Sanden WMH; Schmeink CE; Lenselink CH; Siebers AG; Massuger LFAG; Melchers WJG; Bekkers RLM
    PLoS One; 2018; 13(10):e0206219. PubMed ID: 30356297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
    Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
    Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Application of high-risk human papillomavirus testing in women with abnormal cytology].
    Ou H; Bian ML; Zhang XY; Chen QY; Li M; Chen Y; Liu J
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):608-11. PubMed ID: 18051714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.